Outsourcing

A Q&A with SAFC and BioReliance about sourcing and risk mitigation for raw materials.

BioPlan's outsourcing survey gives insight on top activities, budgets, and growth trends in biopharmaceutical outsourcing.

This article examines the options to best match needs and spending for quality and regulatory leadership.

The authors present solutions based on a review of current service offerings and their audit experience.

Growth is seen in outsourcing of insect- and plant-cell-based bioproduction expression systems.

Is the contract-only CMO an endangered species?

Will international biomanufacturing outsourcing become mainstream in this decade?

An introduction to a new series on manufacturing within global markets.

The procurement organization rethinks sourcing for maximum efficiency and results.

The European Medicines Agency has added granularity to its biosimilars approval pathway by releasing a guideline on mAbs.

Patrick Jackson of Vindon Scientific offers key considerations for choosing an outsourced sample storage facility.

The manufacturing capacity-sharing model between Merck and MedImmune ushers in a new paradigm of "co-opetition."

Measuring the size of the market for contract manufacturing services requires a careful hand.

Marco Chacon of Paragon Bioservices discusses the challenges associated with outsourced vaccine manufacturing.

The weak global economy adds to the challenges of bio/pharma companies and their suppliers.

Budgets for biopharma activities are gaining in select functional areas, except outsourcing.

Industry wants more innovation, but can suppliers meet customers' needs?

Implementing quality by design makes the determination of quality metrics across CMOs and sponsors essential.

The contract provider needs to know as much as the NDA holder.

Formulators and developers are at the heart of the industry's basic premise-they are saving lives.

Industry experts discuss significant achievements. Plus: What's in store for the future.

Service providers must focus on delivering a superior customer experience.

Future sponsor-contract provider relationships will require more integration.

No matter the time or cost, knowing what's going on inside your facilities is always going to be worth the effort.

A closer look at elastomer changeout times provides one example of using industry knowledge to improve operations and cost.

Recovery audits and other best practices in procurement can improve the bottom line.

Collaboration can begin with a conversation.

Representatives from leading CROs weigh in on key challenges tied to the biopharmaceutical R&D, including issues regarding bioequivalence, platform technologies, process analytics, and more.

The author describes an equation that can be used to define the Quality relationship between a contract manufacturing organization and a client, including how to factor in both party's needs and regulatory commitments.

An architectural wonder teaches the biopharmaceutical industry a valuable lesson in project management.